Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-02
2011-08-02
Thomas, Timothy (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S613000, C435S164000, C548S537000, C564S189000
Reexamination Certificate
active
07989439
ABSTRACT:
The disclosure relates to a compound of formula (I):and salts thereof; wherein Ar, L, A, X, R1, R2, R3, R4a, R4b, and R5are as defined in the disclosure; compositions comprising said compounds, methods for their preparation, intermediates thereto, and the use thereof, particularly as drugs.
REFERENCES:
patent: 2004/0220186 (2004-11-01), Bell et al.
patent: 1 683 796 (2006-07-01), None
patent: WO 02/088090 (2002-11-01), None
patent: WO 2004/094410 (2004-11-01), None
patent: WO 2005/012256 (2005-02-01), None
patent: WO 2006/003440 (2006-01-01), None
patent: WO 2006/018662 (2006-02-01), None
patent: WO 2006/070198 (2006-07-01), None
patent: WO 2006/077414 (2006-07-01), None
patent: WO 2006/077425 (2006-07-01), None
patent: WO 2011001122 (2011-01-01), None
Targat et al “Synthetic inhibitors of interleukin-6 II: 3,5-diaryl pyridines and meta-terphenyls”, Biorganic & Medicinal Chemistry Letters, vol. 5, No. 18, pp. 2143-2146, 1995.
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916.
Horig et al. Journal of Translational Medicine 2004, 2(44).
Sawyer et al “Synthesis and activity of New Aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain”. Journal of Medicinal Chemistry, vol. 46, No. 19, Sep. 11, 2003.
Wolff Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, vol. I: Principles and Practice, Wiley-Interscience 1995, pp. 974-977.
Asahara et al, Tie2 Receptor Ligands, Angiopoietin-1 and Angiopoietin-2, Modulate VEGF-Induced Postnatal Neovascularization, Circ. Res., 1998 (83) pp. 233-240.
Campochiaro, Ocular neovascularisation and excessive vascular permeability, Expert Opin. Biol. Ther., 2004 (4) 9 pp. 1395-1402.
Davis et al, Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning, Cell, 1996 (87) pp. 1161-1169.
Debusk et al, Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway, Experimental Cell Research, 2004 (298) pp. 167-177.
Debusk et al, Tie2 Receptor Tyrosine Kinase, a Major Mediator of Tumor Necrosis Factor alpha-Induced Angiogenesis in Rheumatoid Arthritis, Arthritis & Rheumatism, 2003 (48) 9 pp. 2461-2471.
Dumont et al, Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo, Genes Dev., 1994 (8) pp. 1897-1909.
Ferrara, Vascular Endothelial Growth Factor and the Regulation of Angiogenesis, Rec. Prog. Horm. Res. 2000 (55) pp. 15-36.
Folkman et al, Angiogenesis in cancer, vascular, rheumatoid and other disease, Nature Med., 1995 (1) 1 pp. 27-31.
Giuliani et al, Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis, Blood, 2003 (102) 2 pp. 638-645.
Hangai et al, Systemically Expressed Soluble Tie2 Inhibits Intraocular Neovascularization, Human Gene Therapy, 2001 (12) pp. 1311-1321.
Hasan et al, Intra-tumoural microvessel density in human solid tumours, Br. J. Cancer, 2002 (86) pp. 1566-2577.
Koutroubakis et al, Role of Angiogenesis in Inflammatory Bowel Disease, Inflamm. Bowel Dis., 2006 (12) 6 pp. 515-523.
Kvasnicka et al, Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders, Histol. Histopath., 2004 (19) pp. 1245-1260.
Lee et al, Anti-Vascular Endothelial Growth Factor Treatment Augments Tumor Radiation Response under Normoxic or Hypoxic Conditions 1, Cancer Research, 2000 (60) 19, pp. 5565-5570.
Lin et al, Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2, PNAS, 1998 (95) pp. 8829-8834.
Lin et al, Inhibition of Tumor Anglogenesis Using a Soluble Receptor Establishes a Role for Tie2 in Pathologic Vascular Growth, J. Clin. Invest., 1997 (100) 8 pp. 2072-2078.
Maisonpierre et al, Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis, Science, 1997 (277) pp. 55-60.
Maliba et al, Angiopoietins-1 and -2 are both capable of mediating endothelial PAF synthesis: Intracellular signalling pathways, Cellular Signalling, 2006 (18) pp. 1947-1957.
Melani et al, Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis, Cancer Immunol. Immunother., 2004 (53) pp. 600-608.
Millauer et al, Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types in Vivo, Cancer Research, 1996 (56) pp. 1615-1620.
Morisada et al, Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation, Blood, 2005 (105) 12 pp. 4649-4656.
Nilsson et al, Studies on Carbanilic Acid Esters of Cyclic Amino Alcohols. 4. Esters of Pyrrolidinols and Piperidinols as Local Anesthetics, J. Med. Chem., 1971 (14) 8 pp. 710-714.
Pap et al, Linking Angiogenesis to Bone Destruction in Arthritis, Arthritis & Rheumatism, 2005 (52) 5 pp. 1346-1348.
Peters et al, Functional Significance of Tie2 Signaling in the Adult Vasculature, Recent Prog. Horm. Res., 2004 pp. 51-71.
Shahrara et al, Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue, Arthritis Research, 2002 (4) pp. 201-208.
Strawn et.al, Flk-1 as a Target for Tumor Growth Inhibition, Cancer Research, 1996 (56) pp. 3540-3545.
Streit et al, Antigiogenesis, Lymphangiogenesis, and Melanoma Metastasis, Oncogene, 2003 (22) pp. 3172-3179.
Suri et al, Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis, Cell, 1996 (87) pp. 1171-1180.
Thomas et al, Antiangiogenic Therapy in Leukemia, Acta Haematol., 2001 (106) pp. 190-207.
Xiao et al, Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro, Leukemia Research, 2006 (30) pp. 54-59.
Bjergarde Kirsten
Dodson Mark
Mauger Jacques
Nair Anil
Patek Marcel
Cornet Jean
Sanofi-Aventis
Scully , Scott, Murphy & Presser, P.C.
Thomas Timothy
LandOfFree
Substituted pyrazoles, compositions containing these, method... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrazoles, compositions containing these, method..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrazoles, compositions containing these, method... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2756108